Abstract |
Two double-blind, placebo-controlled, randomised, multicentre, multinational, parallel-group studies were carried out to identify the optimum dose of intranasal sumatriptan for the acute treatment of migraine. Study medication was taken as a single dose through one nostril in the first study, and as a divided dose through two nostrils in the second study. Totals of 245 and 210 patients with a history of migraine were recruited into the one- and two-nostril studies, respectively. In both studies, headache severity had significantly improved at 120 min after doses of 10-40 mg sumatriptan compared to placebo (P < 0.05) and the greatest efficacy rates were obtained with 20 mg sumatriptan. With 20 mg sumatriptan 78% and 74% of patients experienced headache relief in one- and two-nostril studies respectively. Sumatriptan was generally well tolerated, the most frequently reported event being taste disturbance. The results of the two studies are similar and indicate that administering sumatriptan as a divided dose via two nostrils confers no significant advantage over single-nostril administration.
|
Authors | R Salonen, E Ashford, C Dahlöf, R Dawson, N E Gilhus, V Lüben, D Noronha, J M Warter |
Journal | Journal of neurology
(J Neurol)
Vol. 241
Issue 8
Pg. 463-9
(Jul 1994)
ISSN: 0340-5354 [Print] Germany |
PMID | 7964913
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Acute Disease
- Administration, Intranasal
- Adult
- Double-Blind Method
- Drug Tolerance
- Female
- Headache
(drug therapy)
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Nose
(drug effects)
- Sumatriptan
(administration & dosage, adverse effects, therapeutic use)
|